Search - tctmd.com

Displaying 1 - 20 of 420

Sort: Relevancy | Date

News Conference News TCT 2025

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

Yael L. Maxwell

November 07, 2025

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

Presentation TCT 2025

Randomized Comparison of the Supraflex CruzTM vs. SYNERGYTM Drug-Eluting Stents: The Multivessel TALENT Randomized Trial

Presenter: Patrick W. Serruys

October 28, 2025

Presentation TCT 2025

TCT 468: Comparison of Limus and Paclitaxel Drug-Coated Balloons, 2nd-generation or Newer Drug-Eluting Stents, and Balloon Angioplasty: A Network Meta-Analysis of Randomized Controlled Trials

Presenter: Yuko Kiyohara

October 27, 2025

Presentation TCT 2025

TCT 511: Paclitaxel-Coated Balloons versus Newer-Generation Drug-Eluting Stents for De Novo Coronary Artery Lesions: A Meta-Analysis of Randomized Controlled Trials

Presenter: Kamil Bujak

October 27, 2025

Presentation TCT 2025

TCT 502: Drug-Coated Balloons Versus Drug-Eluting Stents for Patients with Diffuse De Novo Coronary Artery Lesions: Insights from the REC-CAGEFREE I Trial

Presenter: Yuehao Lv

October 27, 2025

Presentation TCT 2025

TCT 503: Impact of sex on outcomes in patients treated with drug-coated balloons versus drug-eluting stents for de novo coronary artery lesions: Insights from the REC-CAGEFREE I trial

Presenter: Ping Wang

October 27, 2025

Presentation TCT 2025

TCT 500: Clinical Outcomes of Patients With ST-Elevation Myocardial Infarction Treated With Drug-coated Balloons, Hybrid Strategies, or Drug-eluting Stents

Presenter: Nancy Virginia

October 27, 2025

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

Presentation TCT 2025

TCT 235: Efficacy of Bioresorbable Vascular Scaffold vs Drug-Eluting Stents After PCI : A GRADE-Assessed Systematic Review and Meta-Analysis of Randomised Controlled Trials

Presenter: Sultana Jahan

October 26, 2025

Presentation TCT 2025

TCT 189: Follow-up of Flow-Reserve-Guided Treatment for In-Stent Restenosis of Drug-Eluting Coronary Stents

Presenter: Kornel Kakonyi

October 26, 2025

Presentation TCT 2025

TCT 179: In-Stent Restenosis in Chronic Kidney Failure: Long-Term Outcomes Following Drug-Coated Balloons Versus Thin-Strut Drug-Eluting Stents

Presenter: Rafal Adam Januszek

October 26, 2025

Presentation TCT 2025

TCT 371: Drug-Coated Balloons Versus Drug-Eluting Stents for Side Branch Lesions in Coronary Bifurcations: A Systematic Review and Meta-Analysis

Presenter: Fernando Manuel Quevedo

October 26, 2025

Presentation TCT 2025

TCT 375: Optimizing Treatment for MEDINA 0.0.1 Bifurcation Lesions: A Comparative Evaluation of Drug-Coated Balloons and Drug-Eluting Stents

Presenter: Sunwon Kim

October 26, 2025

Presentation TCT 2025

TCT 174: A Comparative Analysis of Clinical Outcomes in Patients with In-Stent Restenosis Undergoing Percutaneous Coronary Intervention with Drug Coated Balloons and Drug Eluting Stents

Presenter: Haseeb Ur Rahman

October 26, 2025

Presentation TCT 2025

Five-Year Outcomes of Biodegradable-Polymer Versus Durable-Polymer Second-Generation Drug-Eluting Stents: A Collaborative Individual Patient Data Analysis of 40,214 Patients Enrolled in 22 Randomized Trials

Presenter: Daniele Giacoppo

October 25, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

Presentation TCT 2024

TCT 261: Comparison of Clinical Outcomes Between First- and Second-Generation Drug-Eluting Stents in Single Vessel Disease Patients up to 10-Year Follow-up Results

Presenter: Woo Jin Ahn

October 30, 2024

Presentation TCT 2024

Are Metallic Drug Eluting Stents As Good As it Gets?

Presenter: Mahesh Madhavan

October 30, 2024

Presentation TCT 2024

Future Metallic Drug Eluting Stents: New Designs, Platforms, and Components

Presenter: Pieter Smits

October 30, 2024

Advertisement

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Randomized Comparison of the Supraflex CruzTM vs. SYNERGYTM Drug-Eluting Stents: The Multivessel TALENT Randomized Trial

TCT 468: Comparison of Limus and Paclitaxel Drug-Coated Balloons, 2nd-generation or Newer Drug-Eluting Stents, and Balloon Angioplasty: A Network Meta-Analysis of Randomized Controlled Trials

TCT 511: Paclitaxel-Coated Balloons versus Newer-Generation Drug-Eluting Stents for De Novo Coronary Artery Lesions: A Meta-Analysis of Randomized Controlled Trials

TCT 502: Drug-Coated Balloons Versus Drug-Eluting Stents for Patients with Diffuse De Novo Coronary Artery Lesions: Insights from the REC-CAGEFREE I Trial

TCT 503: Impact of sex on outcomes in patients treated with drug-coated balloons versus drug-eluting stents for de novo coronary artery lesions: Insights from the REC-CAGEFREE I trial

TCT 500: Clinical Outcomes of Patients With ST-Elevation Myocardial Infarction Treated With Drug-coated Balloons, Hybrid Strategies, or Drug-eluting Stents

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

TCT 235: Efficacy of Bioresorbable Vascular Scaffold vs Drug-Eluting Stents After PCI : A GRADE-Assessed Systematic Review and Meta-Analysis of Randomised Controlled Trials

TCT 189: Follow-up of Flow-Reserve-Guided Treatment for In-Stent Restenosis of Drug-Eluting Coronary Stents

TCT 179: In-Stent Restenosis in Chronic Kidney Failure: Long-Term Outcomes Following Drug-Coated Balloons Versus Thin-Strut Drug-Eluting Stents

TCT 371: Drug-Coated Balloons Versus Drug-Eluting Stents for Side Branch Lesions in Coronary Bifurcations: A Systematic Review and Meta-Analysis

TCT 375: Optimizing Treatment for MEDINA 0.0.1 Bifurcation Lesions: A Comparative Evaluation of Drug-Coated Balloons and Drug-Eluting Stents

TCT 174: A Comparative Analysis of Clinical Outcomes in Patients with In-Stent Restenosis Undergoing Percutaneous Coronary Intervention with Drug Coated Balloons and Drug Eluting Stents

Five-Year Outcomes of Biodegradable-Polymer Versus Durable-Polymer Second-Generation Drug-Eluting Stents: A Collaborative Individual Patient Data Analysis of 40,214 Patients Enrolled in 22 Randomized Trials

What’s Going to Be Hot at TCT 2025

TCT 261: Comparison of Clinical Outcomes Between First- and Second-Generation Drug-Eluting Stents in Single Vessel Disease Patients up to 10-Year Follow-up Results

Are Metallic Drug Eluting Stents As Good As it Gets?

Future Metallic Drug Eluting Stents: New Designs, Platforms, and Components

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content